CN101018567B - 表达Toll样受体的肿瘤细胞凋亡的诱导 - Google Patents

表达Toll样受体的肿瘤细胞凋亡的诱导 Download PDF

Info

Publication number
CN101018567B
CN101018567B CN2005800308083A CN200580030808A CN101018567B CN 101018567 B CN101018567 B CN 101018567B CN 2005800308083 A CN2005800308083 A CN 2005800308083A CN 200580030808 A CN200580030808 A CN 200580030808A CN 101018567 B CN101018567 B CN 101018567B
Authority
CN
China
Prior art keywords
cell
tlr
tlr3
poly
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800308083A
Other languages
English (en)
Chinese (zh)
Other versions
CN101018567A (zh
Inventor
S·勒贝克
T·伦诺
B·萨劳恩
I·科斯特-因弗尼兹
M·-C·里索恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101018567A publication Critical patent/CN101018567A/zh
Application granted granted Critical
Publication of CN101018567B publication Critical patent/CN101018567B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2005800308083A 2004-07-20 2005-07-19 表达Toll样受体的肿瘤细胞凋亡的诱导 Expired - Fee Related CN101018567B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58961604P 2004-07-20 2004-07-20
US60/589,616 2004-07-20
PCT/US2005/025602 WO2006014653A1 (en) 2004-07-20 2005-07-19 Induction of apoptosis in toll-like receptor expressing tumor cells

Publications (2)

Publication Number Publication Date
CN101018567A CN101018567A (zh) 2007-08-15
CN101018567B true CN101018567B (zh) 2011-07-27

Family

ID=35229744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800308083A Expired - Fee Related CN101018567B (zh) 2004-07-20 2005-07-19 表达Toll样受体的肿瘤细胞凋亡的诱导

Country Status (12)

Country Link
US (2) US20060147456A1 (cg-RX-API-DMAC10.html)
EP (1) EP1768699A1 (cg-RX-API-DMAC10.html)
JP (1) JP2008507530A (cg-RX-API-DMAC10.html)
KR (1) KR20070043795A (cg-RX-API-DMAC10.html)
CN (1) CN101018567B (cg-RX-API-DMAC10.html)
AT (1) ATE511859T1 (cg-RX-API-DMAC10.html)
AU (2) AU2005269733B2 (cg-RX-API-DMAC10.html)
CA (1) CA2574176A1 (cg-RX-API-DMAC10.html)
MX (1) MX2007000770A (cg-RX-API-DMAC10.html)
NO (1) NO20070945L (cg-RX-API-DMAC10.html)
RU (1) RU2401661C9 (cg-RX-API-DMAC10.html)
WO (1) WO2006014653A1 (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20120189643A1 (en) * 2004-11-30 2012-07-26 Carton Jill M Toll Like Receptor 3 Antagonists, Methods and Uses
EP1993553B1 (en) 2006-03-02 2013-05-08 Agency for Science, Technology and Research Methods for cancer therapy and stem cell modulation
AU2007249698A1 (en) 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
JP5115921B2 (ja) * 2007-02-28 2013-01-09 株式会社ペルセウスプロテオミクス 腎癌の診断薬および治療薬
AU2008242540A1 (en) * 2007-04-24 2008-10-30 John Wayne Cancer Institute Functional toll-like receptors (TLR) on melanocytes and melanoma cells and uses thereof
JP2011504462A (ja) * 2007-11-02 2011-02-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍の予防および治療のための方法および化合物
WO2009073152A1 (en) * 2007-11-28 2009-06-11 Smart Tube, Inc. Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample
AU2009215795A1 (en) * 2008-02-21 2009-08-27 University Of Kentucky Research Foundation Ultra-small RNAs as toll-like receptor-3 antagonists
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
WO2010020590A1 (en) * 2008-08-20 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators
US8628762B2 (en) 2008-12-10 2014-01-14 Icahn School Of Medicine At Mount Sinai T-helper cell type 17 lineage-specific adjuvants, compositions and methods
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
KR101250419B1 (ko) * 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제
RU2014103159A (ru) * 2011-07-22 2015-08-27 Павел КАЛИНСКИЙ Опухолесективная модуляция хемокинов
CN102652802A (zh) * 2012-04-18 2012-09-05 南京中医药大学 癌毒方在制备调控肝癌细胞TLRs／NF-κB信号转导药物中的应用
EP2879669A4 (en) 2012-07-29 2016-04-13 Univ Colorado Regents ANTAGONISTS OF THE TOLL LIKE RECEPTOR 1/2 COMPLEX
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN105796594A (zh) * 2016-03-28 2016-07-27 南京大学 一种组合物在制备治疗肿瘤药物中的应用及该组合物的使用方法
CN106191238B (zh) * 2016-07-08 2020-01-10 中国医学科学院基础医学研究所 Tlr3预测肿瘤转移、评估预后和选择防治方案的应用
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN108295060A (zh) * 2018-04-08 2018-07-20 王长国 一种tlr7激动剂在增强cik细胞对肿瘤细胞杀伤力方面的应用
US11969402B2 (en) 2019-05-16 2024-04-30 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111117966A (zh) * 2020-03-02 2020-05-08 南通大学 一种利用乳酸的体外细胞培养方法
CN111579538B (zh) * 2020-04-22 2022-12-30 山东第一医科大学(山东省医学科学院) 一种利用凋亡试剂盒检测循环肿瘤细胞的方法
KR20220158640A (ko) * 2021-05-24 2022-12-01 주식회사 차백신연구소 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물
CN115820646A (zh) * 2022-12-20 2023-03-21 武汉光谷中源药业有限公司 一种增强免疫能力的免疫激动剂及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1040504A (zh) * 1988-06-22 1990-03-21 Hem研究公司 用双链核糖核酸调节淋巴激活素抗性细胞状态

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
RU2136278C1 (ru) * 1998-04-07 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Противоопухолевое средство
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
EP1412390A2 (en) * 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
JP3810731B2 (ja) * 2002-11-29 2006-08-16 独立行政法人科学技術振興機構 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1040504A (zh) * 1988-06-22 1990-03-21 Hem研究公司 用双链核糖核酸调节淋巴激活素抗性细胞状态

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F. Andre等.Targeting Toll like receptor 3 by double stranded RNA inbreast cancer: Results from in vitrostudies and randomized trial..Journal of Clinical Oncology22 14S.2004,22(14S),摘要、表1.
F. Andre等.Targeting Toll like receptor 3 by double stranded RNA inbreast cancer: Results from in vitrostudies and randomized trial..Journal of Clinical Oncology22 14S.2004,22(14S),摘要、表1. *

Also Published As

Publication number Publication date
EP1768699A1 (en) 2007-04-04
AU2005269733A1 (en) 2006-02-09
US20090285779A1 (en) 2009-11-19
RU2401661C9 (ru) 2011-01-27
AU2005269733B2 (en) 2008-10-30
MX2007000770A (es) 2007-03-26
US20060147456A1 (en) 2006-07-06
JP2008507530A (ja) 2008-03-13
RU2007105987A (ru) 2008-08-27
RU2401661C2 (ru) 2010-10-20
CA2574176A1 (en) 2006-02-09
KR20070043795A (ko) 2007-04-25
CN101018567A (zh) 2007-08-15
NO20070945L (no) 2007-02-19
ATE511859T1 (de) 2011-06-15
WO2006014653A1 (en) 2006-02-09
AU2008249173A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
RU2401661C9 (ru) Индукция апоптоза в опухолевых клетках, экспрессирующих toll-подобный рецептор
US20240043541A1 (en) Methods for treating hematologic cancers
Zhang et al. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner
TWI725966B (zh) 癌症組合療法
ES2985394T3 (es) Combinación de un antagonista de PD-1 y un oligonucleótido de tipo CpG-C para el tratamiento del cáncer
US20180016555A1 (en) Slamf1 antagonists and uses thereof
US20200182858A1 (en) Methods of treatment with cd80 extracellular domain polypeptides
US20220111069A1 (en) Immunoswitch nanoparticles for reprogrammed t cell responses
Yigit et al. A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells
US20250249073A1 (en) Treatment of immunosuppressed subjects
US12158399B2 (en) CaMKK2 inhibitor compositions and methods of using the same
US20170247422A1 (en) Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
Takizawa et al. Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-κB independent pathway
Børset et al. Apoptosis, proliferation and NF‐κB activation induced by agonistic Fas antibodies in the human myeloma cell line OH‐2: amplification of Fas‐mediated apoptosis by tumor necrosis factor
Dummer Emerging drugs in cutaneous T-cell lymphomas
Dona et al. Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses
Parihar Characterization of the natural killer cell cytokine response to antibody-coated tumor cells
Ali Natural killer cells dictate outcomes of infection by orchestrating innate and adaptive immunity
Anraku Regulatory T cell blockade combined with pemetrexed in malignant pleural mesothelioma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110727

Termination date: 20120719